SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Fumiaki Kobayashi, Manabu Kuroki, A new proportion measure of the treatment effect captured by candidate surrogate endpoints, Statistics in Medicine, 2014, 33, 19
  2. 2
    Masataka Taguri, Yasutaka Chiba, A principal stratification approach for evaluating natural direct and indirect effects in the presence of treatment-induced intermediate confounding, Statistics in Medicine, 2014, 33, 29
  3. 3
    Lesley A. Inker, Andrew S. Levey, Kruti Pandya, Nicholas Stoycheff, Aghogho Okparavero, Tom Greene, Early Change in Proteinuria as a Surrogate End Point for Kidney Disease Progression: An Individual Patient Meta-analysis, American Journal of Kidney Diseases, 2014, 64, 1, 74

    CrossRef

  4. 4
    Tom Loeys, Beatrijs Moerkerke, An Raes, Yves Rosseel, Stijn Vansteelandt, Estimation of Controlled Direct Effects in the Presence of Exposure-Induced Confounding and Latent Variables, Structural Equation Modeling: A Multidisciplinary Journal, 2014, 21, 3, 396

    CrossRef

  5. 5
    E. E. Gabriel, P. B. Gilbert, Evaluating principal surrogate endpoints with time-to-event data accounting for time-varying treatment efficacy, Biostatistics, 2014, 15, 2, 251

    CrossRef

  6. 6
    Julian Wolfson, Lisa Henn, Hard, harder, hardest: principal stratification, statistical identifiability, and the inherent difficulty of finding surrogate endpoints, Emerging Themes in Epidemiology, 2014, 11, 1, 14

    CrossRef

  7. 7
    Ariel Alonso, Wim Van der Elst, Geert Molenberghs, Marc Buyse, Tomasz Burzykowski, On the relationship between the causal-inference and meta-analytic paradigms for the validation of surrogate endpoints, Biometrics, 2014, 70, 3
  8. 8
    M. R. Elliott, A. S. C. Conlon, Y. Li, N. Kaciroti, J. M. G. Taylor, Surrogacy marker paradox measures in meta-analytic settings, Biostatistics, 2014,

    CrossRef

  9. 9
    Tom Greene, Chia-Chen Teng, Lesley A. Inker, Andrew Redd, Jian Ying, Mark Woodward, Josef Coresh, Andrew S. Levey, Utility and Validity of Estimated GFR–Based Surrogate Time-to-Event End Points in CKD: A Simulation Study, American Journal of Kidney Diseases, 2014, 64, 6, 867

    CrossRef

  10. 10
    Ying Huang, Peter B. Gilbert, Julian Wolfson, Design and Estimation for Evaluating Principal Surrogate Markers in Vaccine Trials, Biometrics, 2013, 69, 2
  11. 11
    Marshall M. Joffe, Discussion on “Surrogate Measures and Consistent Surrogates”, Biometrics, 2013, 69, 3
  12. 12
    Judea Pearl, Discussion on “Surrogate Measures and Consistent Surrogates”, Biometrics, 2013, 69, 3
  13. 13
    Tyler J. VanderWeele, Rejoinder, Biometrics, 2013, 69, 3
  14. 14
    Manabu Kuroki, Sharp bounds on causal effects using a surrogate endpoint, Statistics in Medicine, 2013, 32, 25
  15. 15
    Geert Molenberghs, Ariel Alonso Abad, Wim van der Elst, Tomasz Burzykowski, Marc Buyse, Surrogate end points: when should they be used?, Clinical Investigation, 2013, 3, 12, 1147

    CrossRef

  16. 16
    S. G. Baker, B. S. Kramer, Surrogate Endpoint Analysis: An Exercise in Extrapolation, JNCI Journal of the National Cancer Institute, 2013, 105, 5, 316

    CrossRef

  17. 17
    Tyler J. VanderWeele, Surrogate Measures and Consistent Surrogates, Biometrics, 2013, 69, 3
  18. 18
    Debashis Ghosh, A causal framework for surrogate endpoints with semi-competing risks data, Statistics & Probability Letters, 2012, 82, 11, 1898

    CrossRef

  19. 19
    J. Y. Dai, J. P. Hughes, A unified procedure for meta-analytic evaluation of surrogate end points in randomized clinical trials, Biostatistics, 2012, 13, 4, 609

    CrossRef

  20. 20
    Xiaopeng Miao, Yong-Cheng Wang, Ashis Gangopadhyay, An entropy-based nonparametric test for the validation of surrogate endpoints, Statistics in Medicine, 2012, 31, 14
  21. 21
    M. P. Fay, D. A. Follmann, F. Lynn, J. M. Schiffer, G. V. Stark, R. Kohberger, C. P. Quinn, E. O. Nuzum, Anthrax Vaccine-Induced Antibodies Provide Cross-Species Prediction of Survival to Aerosol Challenge, Science Translational Medicine, 2012, 4, 151, 151ra126

    CrossRef

  22. 22
    Michael J. Daniels, Jason A. Roy, Chanmin Kim, Joseph W. Hogan, Michael G. Perri, Bayesian Inference for the Causal Effect of Mediation, Biometrics, 2012, 68, 4
  23. 23
    Carlo Berzuini, Stijn Vansteelandt, Luisa Foco, Roberta Pastorino, Luisa Bernardinelli, Direct Genetic Effects and Their Estimation From Matched Case-Control Data, Genetic Epidemiology, 2012, 36, 6
  24. 24
    Geert Molenberghs, Discussion Contribution to 091037PR4 (Ghosh, Taylor, and Sargent), Biometrics, 2012, 68, 1
  25. 25
    Yue Wang, Robin Mogg, Jared Lunceford, Evaluating Correlation-Based Metric for Surrogate Marker Qualification within a Causal Correlation Framework, Biometrics, 2012, 68, 2
  26. 26
    James Y. Dai, Peter B. Gilbert, Benoît R. Mâsse, Partially Hidden Markov Model for Time-Varying Principal Stratification in HIV Prevention Trials, Journal of the American Statistical Association, 2012, 107, 497, 52

    CrossRef

  27. 27
    Stephen D. Walter, Xin Sun, Diane Heels-Ansdell, Gordon Guyatt, Treatment effects on patient-important outcomes can be small, even with large effects on surrogate markers, Journal of Clinical Epidemiology, 2012, 65, 9, 940

    CrossRef

  28. 28
    Alessandra Mattei, Fabrizia Mealli, Augmented designs to assess principal strata direct effects, Journal of the Royal Statistical Society: Series B (Statistical Methodology), 2011, 73, 5
  29. 29
    Y. Li, J. M. G. Taylor, M. R. Elliott, D. J. Sargent, Causal assessment of surrogacy in a meta-analysis of colorectal cancer trials, Biostatistics, 2011, 12, 3, 478

    CrossRef

  30. 30
    Ying Huang, Peter B. Gilbert, Comparing Biomarkers as Principal Surrogate Endpoints, Biometrics, 2011, 67, 4
  31. 31
    Torben Martinussen, Stijn Vansteelandt, Mette Gerster, Jacob von Bornemann Hjelmborg, Estimation of direct effects for survival data by using the Aalen additive hazards model, Journal of the Royal Statistical Society: Series B (Statistical Methodology), 2011, 73, 5
  32. 32
    Tracy L. Nolen, Michael G. Hudgens, Randomization-Based Inference Within Principal Strata, Journal of the American Statistical Association, 2011, 106, 494, 581

    CrossRef

  33. 33
    Zhenguo Wu, Ping He, Zhi Geng, Sufficient conditions for concluding surrogacy based on observed data, Statistics in Medicine, 2011, 30, 19
  34. 34
    Yun Li, Jeremy M.G. Taylor, Michael R. Elliott, A Bayesian Approach to Surrogacy Assessment Using Principal Stratification in Clinical Trials, Biometrics, 2010, 66, 2
  35. 35
    M. R. Elliott, T. E. Raghunathan, Y. Li, Bayesian inference for causal mediation effects using principal stratification with dichotomous mediators and outcomes, Biostatistics, 2010, 11, 2, 353

    CrossRef

  36. 36
    S. Vansteelandt, Estimation of controlled direct effects on a dichotomous outcome using logistic structural direct effect models, Biometrika, 2010, 97, 4, 921

    CrossRef

  37. 37
    Debashis Ghosh, Michael R. Elliott, Jeremy M. G. Taylor, Links between analysis of surrogate endpoints and endogeneity, Statistics in Medicine, 2010, 29, 28
  38. 38
    T. J. VanderWeele, S. Vansteelandt, Odds Ratios for Mediation Analysis for a Dichotomous Outcome, American Journal of Epidemiology, 2010, 172, 12, 1339

    CrossRef

  39. 39
    Shiro Tanaka, Koji Oba, Kenichi Yoshimura, Satoshi Teramukai, Statistical Criteria for Surrogate Endpoint and Applications: A Review, Japanese Journal of Biometrics, 2010, 31, 1, 23

    CrossRef

  40. 40
    Julian Wolfson, Peter Gilbert, Statistical Identifiability and the Surrogate Endpoint Problem, with Application to Vaccine Trials, Biometrics, 2010, 66, 4
  41. 41
    Stijn Vansteelandt, Estimating Direct Effects in Cohort and Case–Control Studies, Epidemiology, 2009, 20, 6, 851

    CrossRef

  42. 42
    Andrew S. Levey, Daniel Cattran, Aaron Friedman, W. Greg Miller, John Sedor, Katherine Tuttle, Bertram Kasiske, Thomas Hostetter, Proteinuria as a Surrogate Outcome in CKD: Report of a Scientific Workshop Sponsored by the National Kidney Foundation and the US Food and Drug Administration, American Journal of Kidney Diseases, 2009, 54, 2, 205

    CrossRef

  43. 43
    Stijn Vansteelandt, Estimation of Direct and Indirect Effects,
  44. 44
    Judea Pearl, The Mediation Formula: A Guide to the Assessment of Causal Pathways in Nonlinear Models,